Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 274 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR The art of practicing sustainable science April 22, 2021 FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... March 23, 2026 Welcome to Caring Connections November 18, 2020 How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives December 14, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Melphalan FDA Approves Imetelstat for Low- To Intermediate-1 Risk Myelodysplastic Syndromes with... Witness the Moment of Absolute Triumph as Baltimore Woman Is Finally... New tool to tackle gaps in public’s knowledge of blood cancer...
